Championing non-invasive negative pressure breathing support for treatment of respiratory disease.
Even before the COVID-19 pandemic 1.5 million people, including 700,000 children, died annually of pneumonia worldwide; over 4,000 every day. It is the fourth most common cause of death.
Chronic Obstructive Pulmonary Disease (COPD) additionally kills 3.5 million people worldwide annually and is relentlessly increasing. In 2019, among 28 EU member states, costs of €380 billion were attributable to the care of patients with chronic respiratory diseases.
Prevention of respiratory disease worldwide is vitally important ,but unfortunately a long way in the future. All the countries of the world,especially LMIC nations, need access to safe, reliable and effective treatment for critical respiratory illness. Increasing understanding of COVID-19 pneumonia has shown that non-invasive forms of ventilatory support, which do not require patients to be anaesthetised and intubated, are preferable and advantageous for many patients.
Exovent is a charity led by a team of eminent Critical Care Specialists,Anaesthetists,Respiratory Physicians,Paediatricians, ENT/Airway Surgeons, Critical Care and Research Nurses, Senior Engineers and Commercial Professionals. We believe that Continuous Negative Extrathoracic Pressure (CNEP), and Negative Pressure Ventilation (NPV) are valuable methods of breathing support for the treatment of acute pneumonia, including COVID-19, and chronic pulmonary disease of many types.
The team has developed a new type of negative pressure ventilatory support device, which is by comparison inexpensive, lightweight, easy to use, and comfortable for awake patients.
Initially, during the COVID pandemic,(in the space of eight weeks), working with the Warwick Manufacturing Group and with enormous support from Marshall Aerospace & Defence Group, extensively tested prototypes were developed.Healthy Human Trials were published in Anaesthesia Journal in 2021 Relentless progress continues to be made with our manufacturer Portsmouth Aviation to deliver the UK and Europe device through the MDR approval process and with the Medical Health Regulations Authority (MHRA) in the UK to obtain a CE mark.
